StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson pROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — U.S. operational growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q4 2021
-12.8%
Period ended Jan 2, 2022
Change on a year earlier
+34.1 pts
-46.9% in Q4 2020
History
17 quarters
Since Q4 2017
Sources
17
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — U.S. operational growth YoY (%) (%)Year on yearSource
Q4 2021Jan 2, 2022-12.8%+34.1 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
Q3 2021Oct 3, 2021-30.9%+14.5 ptsForm 8-K (a2021q3exhibit991.htm, filed 2021-10-19) ↗
Q2 2021Jul 4, 2021-16.3%+22.0 ptsForm 8-K (a2021q2exhibit991final.htm, filed 2021-07-21) ↗
Q1 2021Apr 4, 2021-18.3%+30.2 ptsForm 8-K (a2021q1exhibit991final.htm, filed 2021-04-20) ↗
Q4 2020Jan 3, 2021-46.9%-25.3 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Q3 2020Sep 27, 2020-45.4%-15.8 ptsForm 8-K (a2020q3exhibit991.htm, filed 2020-10-13) ↗
Q2 2020Jun 28, 2020-38.3%-10.8 ptsForm 8-K (a2020q2exhibit991.htm, filed 2020-07-16) ↗
Q1 2020Mar 29, 2020-48.5%-26.9 ptsForm 8-K (a2020q1exhibit991.htm, filed 2020-04-14) ↗
Q4 2019Dec 29, 2019-21.6%-13.7 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
Q3 2019Sep 29, 2019-29.6%-35.6 ptsForm 8-K (a2019q3exhibit991.htm, filed 2019-10-15) ↗
Q2 2019Jun 30, 2019-27.5%-17.2 ptsForm 8-K (a2019q2exhibit9915.htm, filed 2019-07-16) ↗
Q1 2019Mar 31, 2019-21.6%-33.4 ptsForm 8-K (a2019q1exhibit9915.htm, filed 2019-04-16) ↗
Q4 2018Dec 30, 2018-7.9%+3.9 ptsForm 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗
Q3 2018Sep 30, 20186.0%–Form 8-K (a8k2018q3exhibit9915.htm, filed 2018-10-16) ↗
Q2 2018Jul 1, 2018-10.3%–Form 8-K (a8k2018q2exhibit9915.htm, filed 2018-07-17) ↗
Q1 2018Apr 1, 201811.8%–Form 8-K (a8k2018q1exhibit9915.htm, filed 2018-04-17) ↗

Cite this data

StockData. (2026). Johnson & Johnson PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — U.S. operational growth YoY (%) (%), quarterly Q4 2017–Q4 2021 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_procrit_us_ops_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.